The company's Circulating Tumor Cells screening device distinguishes healthy cells from tumor cells, even in very small samples.
BioView Ltd. (TASE:BIOV) has sold its first Circulating Tumor Cells (CTC) screening device to Taiwan Academia Sinica for NIS 600,000. The company believes that the sale could lead to more sales of its systems in Asia.
BioView's system distinguishes healthy cells from tumor cells based on blood circulation, and can diagnose tumors from very small samples.
Academia Sinica was founded in 1928, and currently has 250 members and 830 researchers at its 24 research institutes and seven centers.
BioView's share price was unchanged at NIS 1.75 today, giving a market cap of NIS 24 million.
Published by Globes [online], Israel business news - www.globes-online.com - on January 10, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012